- Home
- IDR vs ACTU Comparison
IDR vs ACTU Comparison
Compare IDR & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDR
- ACTU
- Stock Information
- Founded
- IDR 1996
- ACTU 2015
- Country
- IDR United States
- ACTU United States
- Employees
- IDR N/A
- ACTU N/A
- Industry
- IDR Precious Metals
- ACTU
- Sector
- IDR Basic Materials
- ACTU
- Exchange
- IDR Nasdaq
- ACTU NYSE
- Market Cap
- IDR 154.1M
- ACTU 135.0M
- IPO Year
- IDR N/A
- ACTU 2024
- Fundamental
- Price
- IDR $13.76
- ACTU $7.47
- Analyst Decision
- IDR Strong Buy
- ACTU Strong Buy
- Analyst Count
- IDR 1
- ACTU 1
- Target Price
- IDR $17.50
- ACTU $20.00
- AVG Volume (30 Days)
- IDR 315.9K
- ACTU 85.1K
- Earning Date
- IDR 07-29-2025
- ACTU 05-15-2025
- Dividend Yield
- IDR N/A
- ACTU N/A
- EPS Growth
- IDR 144.40
- ACTU N/A
- EPS
- IDR 0.62
- ACTU N/A
- Revenue
- IDR $27,144,971.00
- ACTU N/A
- Revenue This Year
- IDR $9.76
- ACTU N/A
- Revenue Next Year
- IDR N/A
- ACTU N/A
- P/E Ratio
- IDR $22.27
- ACTU N/A
- Revenue Growth
- IDR 67.42
- ACTU N/A
- 52 Week Low
- IDR $8.90
- ACTU $5.51
- 52 Week High
- IDR $19.75
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- IDR 48.18
- ACTU N/A
- Support Level
- IDR $14.00
- ACTU N/A
- Resistance Level
- IDR $14.79
- ACTU N/A
- Average True Range (ATR)
- IDR 0.62
- ACTU 0.00
- MACD
- IDR 0.13
- ACTU 0.00
- Stochastic Oscillator
- IDR 43.72
- ACTU 0.00
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.